Letter from the Remuneration Committee Chair
Dearest Shareholders, As the incoming Chair of the Company, in short letters...
Read MoreCLINUVEL Chair to Retire Following FDA Approval
CLINUVEL PHARMACEUTICALS LTD today announced that Mr Stan McLiesh will retire from...
Read MoreAppendix 4G and Corporate Governance Statement
CLINUVEL PHARMACEUTICALS Corporate Governance Statement has been updated and is available...
Read MoreAnnual Report to shareholders
CLINUVEL’s Annual Report for the year ended 30 June 2019. Download...
Read MoreNotice of Annual General Meeting/Proxy Form
This Explanatory Memorandum has been prepared for the Shareholders of the...
Read MoreAudio Transcript Investor Teleconference
An audio transcript of the investor teleconference held yesterday can be...
Read MoreFDA Grants Marketing Approval For SCENESSE
It is a privilege for CLINUVEL PHARMACEUTICALS LTD to announce the...
Read MoreTrading Halt
The securities of Clinuvel Pharmaceuticals Limited (CUV) will be placed in...
Read MoreCLINUVEL Renews Employment Agreement With CEO
CLINUVEL PHARMACEUTICALS LTD today announced that it has renewed the Employment...
Read MoreFDA Clarifies SCENESSE® PDUFA Date
CLINUVEL PHARMACEUTICALS LTD today announced that the US Food and Drug...
Read MoreCLINUVEL Confirms AGM Date
CLINUVEL PHARMACEUTICALS LTD today announced it will hold its 2019 Annual...
Read MoreCLINUVEL Appoints New Director
CLINUVEL PHARMACEUTICALS LTD today announced the appointment of Susan (Sue) Smith...
Read More